Traditionally prognostic factors include age, number of positive axillary lymph nodes, tumor size, tumor grade, lymphatic and vascular invasion, and immunohistochemical biomarkers such as ER/progesterone receptor (PR) status, HER2, and Ki-67 [120, 121]. This evidence concerns the gene ERBB2 and neoplasm.